OpenAI's drug discovery model just became a government biodefense tool.
GPT-Rosalind launched in April 2026 for pharma research, topping the BixBench bioinformatics benchmark at 0.751 Pass@1. On May 29, OpenAI extended it to US government biodefense partners including Lawrence Livermore National Laboratory and CEPI. The benchmark holds. The governance structure is more restricted than anything OpenAI has shipped before.